专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2008155669A3 ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：用于治疗神经损伤性疾病的亚胺酰吡咯烷酮衍生物
公开(公告)号：WO2008155669A3
公开(公告)日：2009-06-04
申请号：PCT/IB2008002446
申请日：2008-05-14
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , CHEREZE NATHALIE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： CHEREZE NATHALIE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
IPC分类号： C07D239/36 , A61K31/513 , A61P25/00
CPC分类号： C07D239/36
摘要： A pyrimidone derivative represented by Formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 4 or 5-pyrimidine ring or a 4-pyridine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a benzene ring, a naphthalene ring or a benzyl group; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, an heteroaryl group optionally substituted by a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, C1-6 alkoxy group optionally substituted by a C3-5 cycloalkyl group, a C1-2 perhalogenated alkoxy group, a C1-6 alkylsulfonyl group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group or a C2-12 dialkylamino group, an acetoxy group or an aminosulfonyl group; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom or a C1-6 alkyl group; R5 represents a hydrogen atom, a C1-6 alkyl group; R6 represents a hydrogen atom, a C1-6 alkyl group; R7 represents a hydrogen atom or a C1-6 alkyl group; n represents 0 to 3 and m represents 0 in the form of a free base or of an addition salt with an acid.
摘要翻译：式（I）表示的嘧啶酮衍生物或其盐或其溶剂合物或其水合物：其中：X表示2个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Z表示键，氧原子，被氢原子或C1-3烷基取代的氮原子，硫原子，任选被一个或两个选自C 1-6烷基，羟基的基团取代的亚甲基基团，C1-6烷氧基，C1-2全卤代烷基或氨基; R1表示2,4或5-嘧啶环或4-吡啶环，该环任选被C 1-6烷基，C 1-6烷氧基或卤素原子取代; R2表示苯环，萘环或苄基; 该环任选被1至4个选自C 1-6烷基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基，卤素原子，C 1-2全卤代烷基， C 1-3卤代烷基，羟基，任选被C 1-6烷基取代的杂芳基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基，任选被 C3-5环烷基，C1-2全卤代烷氧基，C1-6烷基磺酰基，硝基，氰基，氨基，C1-6单烷基氨基或C2-12二烷基氨基，乙酰氧基或氨基磺酰基; R3表示氢原子，C1-6烷基或卤素原子; R4表示氢原子或C1-6烷基; R5表示氢原子，C1-6烷基; R6表示氢原子，C1-6烷基; R7表示氢原子或C1-6烷基; n表示0〜3，m表示0以游离碱或与酸形成的加成盐形式。

12. 发明申请

WO2009156861A3 SUBSTITUTED PYRIMIDONE DERIVATIVES 审中-公开
标题翻译：取代的吡咯烷酮衍生物
公开(公告)号：WO2009156861A3
公开(公告)日：2010-04-01
申请号：PCT/IB2009006486
申请日：2009-06-25
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVENTIS , LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
IPC分类号： A61K31/519 , A61P25/00 , C07D471/04
CPC分类号： C07D471/04 , A61K31/519
摘要： Pyrimidone derivatives of formula (I) wherein: R1 represents a 4-pyridine ring; R2 represents a hydrogen atom; R3 represents a hydrogen atom; R4 represents : a hydrogen atom; a phenyl ring, this ring being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 halogenated alkoxy group, R5 represents a hydrogen atom, a C1-6 alkyl group, a 4-pyridine group, a phenyl group, these groups being optionally substituted, R6 represents a hydrogen atom, a C1-6 alkyl group, a benzyloxy group, a phenyl C1-6 alkyl group, these groups being optionally substituted, in form of a free base or of an addition salt with an acid. Use in therapeutic.
摘要翻译：式（I）的嘧啶酮衍生物其中：R1表示4-吡啶环; R2表示氢原子; R3表示氢原子; R4表示：氢原子; 苯环，该环任选被1至4个选自C 1-6烷基，卤素原子，C 1-2卤代烷基，羟基，C 1-6烷氧基，C 1-2 卤代烷氧基，R5表示氢原子，C1-6烷基，4-吡啶基，苯基，这些基团任意取代，R6表示氢原子，C1-6烷基，苄氧基，苯基C 1-6烷基，这些基团任选被取代，以游离碱的形式或与酸的加成盐形式。用于治疗。

13. 发明申请

WO2009156861A2 SUBSTITUTED PYRIMIDONE DERIVATIVES 审中-公开
标题翻译：取代的吡咯烷酮衍生物
公开(公告)号：WO2009156861A2
公开(公告)日：2009-12-30
申请号：PCT/IB2009006486
申请日：2009-06-25
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVENTIS , LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
IPC分类号： A61K31/519 , A61P25/00 , C07D471/04
CPC分类号： C07D471/04 , A61K31/519
摘要： Pyrimidone derivatives of formula (I) wherein: R1 represents a 4-pyridine ring; R2 represents a hydrogen atom; R3 represents a hydrogen atom; R4 represents : a hydrogen atom; a phenyl ring, this ring being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 halogenated alkoxy group, R5 represents a hydrogen atom, a C1-6 alkyl group, a 4-pyridine group, a phenyl group, these groups being optionally substituted, R6 represents a hydrogen atom, a C1-6 alkyl group, a benzyloxy group, a phenyl C1-6 alkyl group, these groups being optionally substituted, in form of a free base or of an addition salt with an acid. Use in therapeutic.
摘要翻译：式（I）的嘧啶酮衍生物其中：R1表示4-吡啶环; R2表示氢原子; R3表示氢原子; R4表示：氢原子; 苯环，该环任选被1至4个选自C 1-6烷基，卤素原子，C 1-2卤代烷基，羟基，C 1-6烷氧基，C 1-2 卤代烷氧基，R5表示氢原子，C1-6烷基，4-吡啶基，苯基，这些基团任意取代，R6表示氢原子，C1-6烷基，苄氧基，苯基C 1-6烷基，这些基团任选被取代，以游离碱的形式或与酸的加成盐形式。用于治疗。

14. 发明申请

WO2009156860A3 4-(PYRIDIN-4-YL)-1H-(1, 3, 5)TRIAZIN-2-ONE DERIVATIVES AS GSK3-BETA INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开
标题翻译： 4-（PYRIDIN-4-YL）-1H-（1,3,5）TRIAZIN-2-ONE衍生物作为用于治疗神经损伤性疾病的GSK3-β抑制剂
公开(公告)号：WO2009156860A3
公开(公告)日：2010-03-04
申请号：PCT/IB2009006463
申请日：2009-06-25
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVENTIS , LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
IPC分类号： C07D401/04 , A61K31/53 , A61P3/10 , A61P25/28 , A61P33/06 , A61P35/00 , C07D487/04
CPC分类号： C07D401/04 , C07D487/04
摘要： A triazinone derivative represented by formula (I) wherein: Z represents a bond, a carbonyl group, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a Ci-ß alkoxy group; R1 represents a 4-pyridine ring; R2 represents a hydrogen atom, a C1-6 alkyl; R3 represents a hydrogen atom, a C1-6 alkyl group; R2 and R3 may form together a 6 membered cycle with the nitrogens caring R2 and R3 optionally substituted; R4 represents: a phenyl ring, being optionally substituted; n represents 0 to 2; in form of a free base or of an addition salt with an acid. The compounds of the present invention have GSK3ß inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activity of GSK3ß and more particularly of neurodegenerative diseases.
摘要翻译：由式（I）表示的三嗪酮衍生物，其中：Z表示键，羰基，任选被一个或两个选自C 1-6烷基，羟基，C 1-6烷氧基的基团取代的亚甲基; R1表示4-吡啶环; R2表示氢原子，C1-6烷基; R3表示氢原子，C1-6烷基; R2和R3可以一起形成6元环与关心R2和R3任选取代的氮; R4表示：任选被取代的苯环; n表示0〜2; 以游离碱的形式或与酸形成的加成盐。本发明的化合物具有GSK3β抑制活性，可用作用于预防和/或治疗由GSK3β的异常活性引起的疾病，特别是神经变性疾病的药物的活性成分。

15. 发明申请

WO2008155666A3 HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：用于治疗神经损伤性疾病的异氟醚取代的吡咯烷酮衍生物
公开(公告)号：WO2008155666A3
公开(公告)日：2009-04-09
申请号：PCT/IB2008002429
申请日：2008-05-14
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , CHEREZE NATHALIE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： CHEREZE NATHALIE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
IPC分类号： C07D239/38 , A61K31/495 , A61P3/00 , A61P25/00 , A61P35/00 , C07D401/14 , C07D403/14 , C07D409/14 , C07D417/14 , C07D471/04
CPC分类号： C07D403/14 , C07D239/38 , C07D401/14 , C07D409/14 , C07D417/14 , C07D471/04
摘要： A pyrimidone derivative represented by Formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Formula (I). The compounds (I) are suitable for the treatment of neurodegenerative diseases.
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐或其溶剂合物或其水合物：式（I）。化合物（I）适用于治疗神经变性疾病。

16. 发明申请

WO2008155668A3 HETEROARYLAMIDE PYRIMIDONE COMPOUNDS 审中-公开
标题翻译：异丁酰胺吡咯烷酮化合物
公开(公告)号：WO2008155668A3
公开(公告)日：2009-03-12
申请号：PCT/IB2008002445
申请日：2008-05-14
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
IPC分类号： C07D401/12 , A61K31/513 , A61P3/00 , A61P25/00 , C07D239/36 , C07D403/12 , C07D405/12 , C07D409/12
CPC分类号： C07D403/12 , C07D239/36 , C07D401/14 , C07D405/14 , C07D409/14 , C07D471/04
摘要： A pyrimidone derivative represented by Formula (I) or a salt, solvate or a hydrate thereof, wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 4 or 5-pyrimidine ring or a 4- pyridine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a 4-15 membered heterocyclic, group, this group being optionally substituted by 1 to 4 substituents as defined in claim 1; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom or a C1-6 alkyl group;. R5 represents a hydrogen atom, a C1-6 alkyl group; R6 represents a hydrogen atom, ' a C1-6 alkyl group;. R7 represents a hydrogen atom or a C1-6 alkyl group; and n represents 0 to 3 and m represents 1 in the form of a free base or of an addition salt with an acid. and a medicament containing the same as a GSKk inhibitor.
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐，溶剂合物或水合物，其中：X表示两个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Z表示键，氧原子，被氢原子或C1-3烷基取代的氮原子，硫原子，任选被一个或两个选自C 1-6烷基，羟基的基团取代的亚甲基基团，C1-6烷氧基，C1-2全卤代烷基或氨基; R1表示2,4或5-嘧啶环或4-吡啶环，该环任选被C 1-6烷基，C 1-6烷氧基或卤素原子取代; R2表示4-15元杂环基，该基团任选被1至4个如权利要求1所定义的取代基取代; R3表示氢原子，C1-6烷基或卤素原子; R4表示氢原子或C1-6烷基。 R5表示氢原子，C1-6烷基; R6表示氢原子，C1-6烷基。 R7表示氢原子或C1-6烷基; n表示0〜3，m表示1以游离碱或与酸形成的加成盐的形式。和含有与GSKk抑制剂相同的药物。

17. 发明申请

WO2008155670A2 ARYLAMIDE PYRIMIDONE COMPOUNDS 审中-公开
标题翻译： ARYLAMIDE PYRIMIDONE化合物
公开(公告)号：WO2008155670A2
公开(公告)日：2008-12-24
申请号：PCT/IB2008002458
申请日：2008-05-14
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
CPC分类号： C07D403/04 , A61K9/0019 , A61K9/2018 , A61K9/4858 , C07D413/14
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 4 or 5-pyrimidine ring or a 4-pyridine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a benzene ring, a naphthalene ring or a benzyl group; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, an heteroaryl group optionally substituted by a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, C1-6 alkoxy group optionally substituted by a C3-5 cycloalkyl group, a C1-2 perhalogenated alkoxy group, a C1-6 alkylsulfonyl group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group or a C2-12 dialkylamino group, an acetoxy group or an aminosulfonyl group; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom or a C1-6alkyl group; R5 represents a hydrogen atom, a C1-6 alkyl group; R6 represents a hydrogen atom, a C1-6 alkyl group; R7 represents a hydrogen atom or a C1-6 alkyl group; n represents 0 to 3 and m represents 1 in the form of a free base or of an addition salt with an acid.
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐或其溶剂合物或其水合物：其中X表示两个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Z表示键，氧原子，被氢原子或C1-3烷基取代的氮原子，硫原子，任选被一个或两个选自C 1-6烷基，羟基的基团取代的亚甲基基团，C1-6烷氧基，C1-2全卤代烷基或氨基; R1表示2,4或5-嘧啶环或4-吡啶环，该环任选被C 1-6烷基，C 1-6烷氧基或卤素原子取代; R2表示苯环，萘环或苄基; 该环任选被1至4个选自C 1-6烷基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基，卤素原子，C 1-2全卤代烷基， C 1-3卤代烷基，羟基，任选被C 1-6烷基取代的杂芳基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基，任选被 C3-5环烷基，C1-2全卤代烷氧基，C1-6烷基磺酰基，硝基，氰基，氨基，C1-6单烷基氨基或C2-12二烷基氨基，乙酰氧基或氨基磺酰基; R3表示氢原子，C1-6烷基或卤素原子; R4表示氢原子或C1-6烷基; R5表示氢原子，C1-6烷基; R6表示氢原子，C1-6烷基; R7表示氢原子或C1-6烷基; n表示0〜3，m表示1以游离碱或与酸的加成盐形式的1。

18. 发明申请

WO2008078196A2 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES 审中-公开
标题翻译：取代的杂芳基吡啶并嘧啶酮衍生物
公开(公告)号：WO2008078196A2
公开(公告)日：2008-07-03
申请号：PCT/IB2007004409
申请日：2007-12-20
申请人： SANOFI AVENTIS , MITSUBISHI TANABE PHARMA CORP , FAYOL AUDE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
发明人： FAYOL AUDE , GALLET THIERRY , LOCHEAD ALISTAIR , SAADY MOURAD , VERONIQUE CORINNE , YAICHE PHILIPPE
CPC分类号： A01N43/90 , C07D239/70
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y represents two hydrogen atoms, a sulfur atom, an oxygen atom or a Ci-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a Ci-6 alkyl group, a hydroxyl group, a Ci-6 alkoxy group, a Ci_2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring; R2 represents an optionally substituted 4-15 membered heterocyclic group; R3 represents a hydrogen atom, a Ci-6 alkyl group or a halogen atom; R4 and R5 represent, each independently, a hydrogen atom, a Ci-6 alkyl group, optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a Ci-6 alkoxy group; R6 represents a hydrogen atom, a Ci-6 alkyl group; a cycloalkyl group, or a halogen atom; R7 represents a hydrogen atom or a Ci-6 alkyl group; n represents 0 to 3; m represents 0 to 1; o represents 0 to 2; in the form of a free base or of an addition salt with an acid. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3ß, such as Alzheimer disease.
摘要翻译：式（I）代表的嘧啶酮衍生物或其盐，或其溶剂合物或其水合物：其中：Y代表两个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Z代表键，氧原子，氮原子，硫原子，任选被选自C 1-6烷基基团，羟基，C 1-6烷氧基的组中选择一个或两个基团取代的亚甲基，C 1-2氟烷全卤代烷基或氨基; R1代表2,3或4-吡啶环或2,4或5-嘧啶环; R2代表任选取代的4-15元杂环基; R 3代表氢原子，C 1-6烷基或卤素原子; R 4和R 5各自独立地表示氢原子，任选被1至4个选自卤素原子，苯基，羟基或C 1-6烷氧基的取代基取代的C 1-6烷基; R6代表氢原子，C1-6烷基; 环烷基或卤素原子; R 7代表氢原子或C 1-6烷基; n表示0至3; m代表0至1; o代表0至2; 以游离碱或与酸加成盐的形式存在。本发明还涉及包含其所述衍生物或其盐作为用于引起GSK3ß的异常活性，如阿尔茨海默病的神经变性疾病的预防性和/或治疗性治疗的有效成分的药物。

19. 发明申请

WO2004033456A3 1,4-DIAZABICYCLO[3.2.2]NONANECARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF RELATED TO MALFUNCTION OF NICOTINIC RECEPTORS 审中-公开
标题翻译： 1,4-二氮杂双环[3.2.2]壬二酰胺衍生物，其制备和治疗用途与尼古丁受体的功能缺陷有关
公开(公告)号：WO2004033456A3
公开(公告)日：2004-05-27
申请号：PCT/FR0302929
申请日：2003-10-06
申请人： SANOFI SYNTHELABO , GALLI FREDERIC , LARDENOIS PATRICK , LECLERC ODILE , LOCHEAD ALISTAIR
发明人： GALLI FREDERIC , LARDENOIS PATRICK , LECLERC ODILE , LOCHEAD ALISTAIR
IPC分类号： A61P25/00 , C07D519/00 , C07D487/08 , A61K31/55 , A61K31/551
CPC分类号： C07D519/00
摘要： The invention concerns compounds of general formula (I), wherein: X represents a nitrogen atom or a group of formula C-R2; P represents a group of formula C-R3; Q represents a group of formula C-R4; R represents a group of formula C-R5; W represents a group of formula C-R6; or one among the symbols P, Q, R and W represents a nitrogen atom; R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom or an alkyl group; R3, R4, R5 and R6 represent each a hydrogen or halogen atom, or an alkyl, alkoxy, nitro, amino, trifluoromethyl, cyano, amino group or other functional groups. The invention is applicable in therapeutics.
摘要翻译：本发明涉及通式（I）的化合物，其中：X表示氮原子或式C-R2基团; P表示式C-R3的基团; Q表示式C-R4的基团; R表示式C-R5的基团; W表示式C-R6的基团; 符号P，Q，R和W中的一个表示氮原子; R1表示氢原子或烷基; R2表示氢原子或烷基; R 3，R 4，R 5和R 6各自表示氢或卤素原子，或烷基，烷氧基，硝基，氨基，三氟甲基，氰基，氨基或其它官能团。本发明适用于治疗。

20. 发明专利

JP2010189422A PHARMACEUTICAL COMPOSITION CONTAINING 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATIVE 审中-公开
标题翻译：含有2-嘧啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮和7-嘧啶基-2,3-二氢吲哚并[1,2-a]吡啶二酮-5（1H，m）的药物组合物）一个衍生物
公开(公告)号：JP2010189422A
公开(公告)日：2010-09-02
申请号：JP2010097989
申请日：2010-04-21
申请人： Mitsubishi Tanabe Pharma Corp , Sanofi-Aventis , サノフィ−アベンティス , 田辺三菱製薬株式会社
发明人： GALLET THIERRY , LARDENOIS PATRICK , LOCHEAD ALISTAIR , MARGUERIE SEVERINE , NEDELEC ALAIN , SAADY MOURAD , SLOWINSKI FRANCK , YAICHE PHILIPPE
IPC分类号： A61K31/519 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P15/00 , A61P17/02 , A61P17/14 , A61P19/08 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/28 , A61P25/34 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D487/04
CPC分类号： A61K31/519 , A61K31/551 , C07D487/04
摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing a compound useful as an active component of a drug for preventing and/or treating neurodegenerative diseases such as Alzheimer disease. SOLUTION: The pharmaceutical composition contains a substance selected from a group consisting of pyrimidone derivatives represented by formula (I), their salts, their solvates and their hydrates as an active component. COPYRIGHT: (C)2010,JPO&INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式